Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.

Hdl Handle:
http://hdl.handle.net/10147/129369
Title:
Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.
Authors:
Wan Md Adnan, Wan A H; Zaharan, Nur L; Bennett, Kathleen; Wall, Catherine A
Affiliation:
Department of Renal Medicine, Adelaide & Meath Hospital Incorporating National Children Hospital (AMNCH), Dublin 24, Ireland. wahafiz@um.edu.my
Citation:
Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. 2011, 71 (3):458-66 Br J Clin Pharmacol
Journal:
British journal of clinical pharmacology
Issue Date:
Mar-2011
URI:
http://hdl.handle.net/10147/129369
DOI:
10.1111/j.1365-2125.2010.03835.x
PubMed ID:
21284706
Abstract:
(i) To examine the trends in co-prescribing of angiotensin converting enzyme inhibitor (ACEI) and angiotensin-II receptor blocker (ARB) therapy and (ii) to examine the influence of major clinical trials (CALM, COOPERATE, VALIANT and ONTARGET) on co-prescribing.; The Irish HSE-Primary Care Reimbursement Services database was used to identify patients ≥16 years old co-prescribed ACEIs and ARBs between January 2000 and April 2009 (n= 266 554 prescriptions). The rate of prescribing per 1000 general medical services (GMS) scheme population was calculated for each month. Patients with diabetes, hypertension, heart failure and ischaemic heart disease were also identified by prescribing of certain medications. A linear trend test was used to examine prescribing trends. Logistic regression was used to examine prescribing according to patient characteristics. The effects of the major trials on prescribing were examined using segmented regression analysis for 12 months pre- and post-trials.; There was a significant linear trend in overall ACEI and ARB co-prescribing over the study period (P < 0.001). Rate of co-prescribing in January 2000 and April 2009 was 0.16 and 5.72, per 1000 eligible population, respectively. Those 45-64 years old (OR = 2.88, 95% confidence interval (CI) 2.71, 3.06) and ≥65 years (OR = 2.52, 95% CI 2.36, 2.68) were more likely to receive dual therapy compared with those <45 years old. Those with hypertension (OR = 8.85, 95% CI 8.45, 9.27), diabetes (OR = 4.10, 95% CI 3.97, 4.23) and heart failure (OR = 1.78, 95% CI 1.72, 1.84) were more likely to receive dual therapy compared with the general population. Significant increases in prescribing were observed only after the CALM (P= 0.03) and VALIANT (P= 0.007) trials.; Increased co-prescribing of ACEIs and ARBs was observed in Ireland during 2000-09. Prescribing patterns did not appear to be affected by results from major trials.
Item Type:
Article
Language:
en
MeSH:
Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diabetes Mellitus; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Ireland; Male; Middle Aged; Myocardial Ischemia; Physician's Practice Patterns; Regression Analysis; Young Adult
ISSN:
1365-2125

Full metadata record

DC FieldValue Language
dc.contributor.authorWan Md Adnan, Wan A Hen
dc.contributor.authorZaharan, Nur Len
dc.contributor.authorBennett, Kathleenen
dc.contributor.authorWall, Catherine Aen
dc.date.accessioned2011-05-11T08:14:58Z-
dc.date.available2011-05-11T08:14:58Z-
dc.date.issued2011-03-
dc.identifier.citationTrends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. 2011, 71 (3):458-66 Br J Clin Pharmacolen
dc.identifier.issn1365-2125-
dc.identifier.pmid21284706-
dc.identifier.doi10.1111/j.1365-2125.2010.03835.x-
dc.identifier.urihttp://hdl.handle.net/10147/129369-
dc.description.abstract(i) To examine the trends in co-prescribing of angiotensin converting enzyme inhibitor (ACEI) and angiotensin-II receptor blocker (ARB) therapy and (ii) to examine the influence of major clinical trials (CALM, COOPERATE, VALIANT and ONTARGET) on co-prescribing.-
dc.description.abstractThe Irish HSE-Primary Care Reimbursement Services database was used to identify patients ≥16 years old co-prescribed ACEIs and ARBs between January 2000 and April 2009 (n= 266 554 prescriptions). The rate of prescribing per 1000 general medical services (GMS) scheme population was calculated for each month. Patients with diabetes, hypertension, heart failure and ischaemic heart disease were also identified by prescribing of certain medications. A linear trend test was used to examine prescribing trends. Logistic regression was used to examine prescribing according to patient characteristics. The effects of the major trials on prescribing were examined using segmented regression analysis for 12 months pre- and post-trials.-
dc.description.abstractThere was a significant linear trend in overall ACEI and ARB co-prescribing over the study period (P < 0.001). Rate of co-prescribing in January 2000 and April 2009 was 0.16 and 5.72, per 1000 eligible population, respectively. Those 45-64 years old (OR = 2.88, 95% confidence interval (CI) 2.71, 3.06) and ≥65 years (OR = 2.52, 95% CI 2.36, 2.68) were more likely to receive dual therapy compared with those <45 years old. Those with hypertension (OR = 8.85, 95% CI 8.45, 9.27), diabetes (OR = 4.10, 95% CI 3.97, 4.23) and heart failure (OR = 1.78, 95% CI 1.72, 1.84) were more likely to receive dual therapy compared with the general population. Significant increases in prescribing were observed only after the CALM (P= 0.03) and VALIANT (P= 0.007) trials.-
dc.description.abstractIncreased co-prescribing of ACEIs and ARBs was observed in Ireland during 2000-09. Prescribing patterns did not appear to be affected by results from major trials.-
dc.language.isoenen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAngiotensin Receptor Antagonists-
dc.subject.meshAngiotensin-Converting Enzyme Inhibitors-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDiabetes Mellitus-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshHeart Failure-
dc.subject.meshHumans-
dc.subject.meshHypertension-
dc.subject.meshIreland-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMyocardial Ischemia-
dc.subject.meshPhysician's Practice Patterns-
dc.subject.meshRegression Analysis-
dc.subject.meshYoung Adult-
dc.titleTrends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.en
dc.typeArticleen
dc.contributor.departmentDepartment of Renal Medicine, Adelaide & Meath Hospital Incorporating National Children Hospital (AMNCH), Dublin 24, Ireland. wahafiz@um.edu.myen
dc.identifier.journalBritish journal of clinical pharmacologyen
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.